In the United States, a high prevalence of acromegaly and neuroendocrine tumors, along with early access to innovative therapies, supports steady demand for somatostatin-based treatments. Ongoing clinical development, favorable regulatory pathways, and strong specialty pharmacy networks are further strengthening the US market. According to The Insight Partners, the global somatostatin market...